Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Diabetic Retinopathy or Retinal Vein Occlusion
Abroad (travel likely)RecruitingPHASE2
Conditions
Non-Proliferative Diabetic Retinopathy · Retinal Vein Occlusion
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
The Retina Clinic London, London, United Kingdom
Contact: Study coordinator (Paulo Eduardo Stanga) · p.stanga@theretinacliniclondon.com · +44 20 4548 5310Contact: Study coordinator (Sebastian Stanga) · sebastian@theretinacliniclondon.com · +44 20 4548 5310Contact: Principal Investigator (Paulo Eduardo Stanga)
Study leads
Anna Frostegård, MD, PhD
Study Director
Annexin Pharmaceuticals AB